| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-05-29 | Theravectys (France) | €1.2 million | repayable advance | OSEO (France) | Infectious diseases | Credit line |
| 2013-05-28 | ugichem (Austria) | €2.25 million | grant, equity financing | Austria’s Research Promotion Agency FFG (Austria) existing investors |
Inflammatory diseases - Immunological diseases | Grant |
| 2013-05-27 | Merus (The Netherlands) and the SUPPRESSTEM consortium | €6 Million | grant | European Commission’s Seventh Framework Program (FP7) | Cancer - Oncology | Grant |
| 2013-05-24 | Pledpharma (Sweden) | 18.6 million SEK (€2.1 million) | share issue | Cancer - Oncology | Private placement | |
| 2013-05-23 | Serodus (Norway) | NOK 4.050.000 (€ 5.3 million) | IPO | Cardiovascular diseases - Metabolic diseases | IPO | |
| 2013-05-23 | Arsanis Biosciences (Austria) | € 1.4 million | grant | Austrian Research Promotion Agency (Austria) | Infectious diseases | Grant |
| 2013-05-21 | Uniqure (The Netherlands) | € 2.5 million | grant | European Eurostars Programme (EU) | Rare diseases - Neurodegenerative diseases | Grant |
| 2013-05-21 | Oncopeptides (Sweden) | series A financing round | HealthCap (Sweden - Switzerland) | Cancer - Oncology | Fundraising | |
| 2013-05-20 | TheraCoat (Israel) | $7 million (€ 5.43 million) | financing round | Pontifax (Israel) Chaim Hurvitz CHealth Fund (Israel) Ran Nussbaum | Cancer - Oncology - Urological diseases | Fundraising |
| 2013-05-17 | BiolineRx (Israel) | Stifel, Nicolaus & Company (USA) | Establishment of a new subsidiary in the EU | |||
| 2013-05-17 | ElsaLys Biotech (France) | € 2.1 million | first round of financing | Transgene (France) Sofimac Partners (France) | Fundraising | |
| 2013-05-16 | MS Ventures (Germany) | € 100 million | Merck Serono (Germany) | Fundraising | ||
| 2013-05-15 | Genmab (Denmark) | DKK 33.6 million | Cancer - Oncology | Capital increase | ||
| 2013-05-14 | Uniqure (The Netherlands) | € 14.1 million | convertible debt, equity funding | Coller Capital (UK) Forbion Capital Partners (The Netherlands) Gilde Healthcare Partners (The Netherlands) Lupus Alpha (Germany) Grupo Netco | Rare diseases - Genetic diseases | Fundraising |
| 2013-05-13 | Neovacs (France) | €414,839 | OSEO (France) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Fundraising | |
| 2013-05-13 | ProQinase (Germany) Mercachem (The Netherlands) | € 2.5 million | grant | Grant | ||
| 2013-05-08 | Celyad previously known as Cardio3 Biosciences (Belgium) | €19 million | private placement | Cardiovascular diseases | Private placement | |
| 2013-05-03 | GSK (UK) | £5million (€ 5.92 million) | grant | the Wellcome Trust (UK) | Parasitic diseases - Infectious diseases | Grant |
| 2013-04-30 | Erytech Pharma (France) | € 17.7 million | IPO | Cancer - Oncology | IPO | |
| 2013-04-26 | The Biomargin consortium consists of INSERM (France), INSERM Transfert SA IT, (France), Assistance publique - Hôpitaux de Paris (AP – HP) (France, CEA (France), CNRS (France), Katholieke Universiteit Leuven (Belgium),Vlaamse Instelling voor Technologisch Onderzoek -Vito, (Belgium), Mosaiques diagnostics (Germany), Medizinische Hochschule Hanover (Germany), Cardinal Systems (France), Université Paris Descartes (France), AcureOmics (Sweden), Centre hospitalier universitaire de Limoges (France). | € 6 million | grant | European Commission’s Seventh Framework Program (FP7) | Transplantation - Renal diseases - Kidney diseases | Grant |
